Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

<p>Abstract</p> <p>Survivin is a member of the inhibitor of apoptosis protein (IAP) family containing a single baculovirus IAP repeat domain. It is expressed during fetal development but becomes undetectable in terminally differentiated normal adult tissues. We previously reported...

Full description

Bibliographic Details
Main Authors: Minamida Hidetoshi, Mizushima Yasuhiro, Sasaki Kazuaki, Yasoshima Takahiro, Katsuramaki Tadashi, Yamaguchi Koji, Ohmura Tosei, Yagihashi Atsuhito, Yamamoto Masaaki, Kurotaki Takehiro, Idenoue Satomi, Furuhata Tomohisa, Torigoe Toshihiko, Hata Fumitake, Tsuruma Tetsuhiro, Kimura Hiromichi, Akiyama Morifumi, Hirohashi Yoshihiko, Asanuma Hiroko, Tamura Yasuaki, Shimozawa Kumiko, Sato Noriyuki, Hirata Koichi
Format: Article
Language:English
Published: BMC 2004-06-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/2/1/19

Internet

http://www.translational-medicine.com/content/2/1/19

Similar Items